Sanguine Biosciences has announced the expansion of its oncology sample offerings through new partnerships with oncology clinics nationwide. These collaborations enable Sanguine to provide researchers with a broader range of high-quality and minimally invasive biospecimens, including treatment-naive samples critical for advancing cancer discovery and precision medicine.

Through these partnerships, Sanguine now offers researchers access to a growing inventory of oncology biospecimens, including blood, plasma, serum and peripheral blood mononuclear cells (PBMCs), collected using minimally invasive methods to reduce donor burden and accelerate study timelines. Treatment-naive samples, in particular, provide researchers with rare and highly valuable insights into early disease biology, immune responses, biomarkers for diagnostic development and potential therapeutic targets prior to intervention.

Sanguine leverages its integrated technology platform to streamline data and donor engagement. By securely importing Electronic Medical Records (EMRs) directly from clinic systems, Sanguine harmonises rich clinical data with each biospecimen, giving researchers a comprehensive and contextualised dataset. At the same time, individuals can be remotely consented into Sanguine's donor community, allowing clinics and their patients to participate in research without additional infrastructure or operational burden. This seamless integration accelerates access to high-quality samples and data while preserving clinic workflows and patient experience.

Gerald Lee, Co-Founder and Chief Product Officer, Sanguine Biosciences, said, "By leveraging our infrastructure, technology and operations, Sanguine has partnered with over 20 oncology clinics across the United States to create a path for empowering researchers with timely access to a diverse group of the highest-quality patient samples. Our expanded oncology offerings, especially treatment-naive biospecimens, will support breakthrough studies in biomarker discovery, drug development and personalised cancer therapies."

Sanguine's expanded oncology capabilities complement its existing nation-wide donor network, advanced logistics infrastructure and robust data integration services, enabling researchers to obtain treatment-naive oncology samples across multiple cancer types; longitudinal and minimally invasive collections to track disease progression; matched blood products, including plasma, serum and PBMCs and detailed electronic medical records, clinical and demographic metadata to enhance translational insights.

With cancer research evolving rapidly, access to high-quality and clinically-annotated biospecimens remains a critical bottleneck. Sanguine's latest initiative directly addresses this challenge, enabling academic institutions, biotech companies and pharmaceutical researchers to accelerate discoveries and bring new diagnostics and therapies to patients faster.